Research Reports | Market Assessment
May 2016

Age-Related Macular Degeneration | Current Treatment | EU5 | 2016

Anti-vascular endothelial growth factor (VEGF) therapy is the standard of care for treating wet age-related macular degeneration (AMD), with several commercially available options. The continued strong uptake of Eylea in Europe threatens Lucentis’s historical position as the patient-share leader in this market, while use of off-label Avastin differs across the EU5 countries. Additionally, with no currently available treatments, there is commercial opportunity for first-to-market dry AMD therapies. The Age-Related Macular Degeneration Current Treatment Overview provides a synopsis of current treatment goals, key therapies, and medical practice in the G7 markets. The detailed, expanded analysis in Dry and Wet Age-Related Macular Degeneration Current Treatment EU offers a snapshot of how EU5 ophthalmologists are currently managing their dry and wet AMD patients, with a particular focus on the use of anti-VEGF for wet AMD, as well as insight into the factors driving such prescribing habits.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports